MX2021003160A - Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. - Google Patents

Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.

Info

Publication number
MX2021003160A
MX2021003160A MX2021003160A MX2021003160A MX2021003160A MX 2021003160 A MX2021003160 A MX 2021003160A MX 2021003160 A MX2021003160 A MX 2021003160A MX 2021003160 A MX2021003160 A MX 2021003160A MX 2021003160 A MX2021003160 A MX 2021003160A
Authority
MX
Mexico
Prior art keywords
inhibitors
breast cancer
combinations
treatment
tgfb
Prior art date
Application number
MX2021003160A
Other languages
English (en)
Inventor
Flavia Mercer Pernasetti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021003160A publication Critical patent/MX2021003160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a un método para el tratamiento del cáncer de mama mediante la administración de un inhibidor de TGFß en combinación con un inhibidor de CDK a un paciente que lo necesita.
MX2021003160A 2018-09-18 2019-09-16 Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. MX2021003160A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732618P 2018-09-18 2018-09-18
US201862733120P 2018-09-19 2018-09-19
US201962890168P 2019-08-22 2019-08-22
US201962892771P 2019-08-28 2019-08-28
PCT/IB2019/057776 WO2020058820A1 (en) 2018-09-18 2019-09-16 Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2021003160A true MX2021003160A (es) 2021-05-14

Family

ID=68000001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003160A MX2021003160A (es) 2018-09-18 2019-09-16 Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.

Country Status (13)

Country Link
US (1) US20210346384A1 (es)
EP (1) EP3852758A1 (es)
JP (2) JP6952747B2 (es)
KR (1) KR20210060549A (es)
CN (1) CN112969461A (es)
AU (1) AU2019341683A1 (es)
BR (1) BR112021004058A2 (es)
CA (1) CA3112893A1 (es)
IL (2) IL281490A (es)
MX (1) MX2021003160A (es)
SG (1) SG11202102047PA (es)
TW (2) TWI722568B (es)
WO (1) WO2020058820A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843058A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用
WO2023281413A1 (en) * 2021-07-09 2023-01-12 Pfizer Inc. Methods and dosing regimens comprising pf-06873600 for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
EP1648889B1 (en) 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
AU2007297286A1 (en) 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
PL3431475T3 (pl) 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
PL3089971T3 (pl) * 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
JP2019508428A (ja) * 2016-03-15 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド 抗ｅｒｂｂ３抗体を含む組み合わせ療法を用いて、ｅｒ＋、ｈｅｒ２−、ｈｒｇ＋乳癌を治療するための方法
GEP20217234B (en) * 2016-08-15 2021-03-25 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors

Also Published As

Publication number Publication date
TWI722568B (zh) 2021-03-21
JP2020045339A (ja) 2020-03-26
JP6952747B2 (ja) 2021-10-20
WO2020058820A1 (en) 2020-03-26
KR20210060549A (ko) 2021-05-26
TW202026001A (zh) 2020-07-16
AU2019341683A1 (en) 2021-03-18
US20210346384A1 (en) 2021-11-11
CN112969461A (zh) 2021-06-15
TWI763372B (zh) 2022-05-01
TW202123937A (zh) 2021-07-01
JP2021100972A (ja) 2021-07-08
IL290373A (en) 2022-04-01
BR112021004058A2 (pt) 2021-06-01
SG11202102047PA (en) 2021-04-29
CA3112893A1 (en) 2020-03-26
IL281490A (en) 2021-04-29
EP3852758A1 (en) 2021-07-28
JP7046250B2 (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2019007256A (es) Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2022008868A (es) Tratamiento del cancer con tg02.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MY190411A (en) Improved uricase sequences and methods of treatment
MX2020001727A (es) Terapia de combinacion.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2017009246A (es) Farmaco de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.